Mesoblast Limited (MESO): Price and Financial Metrics

Mesoblast Limited (MESO): $3.69

-0.01 (-0.27%)

POWR Rating

Component Grades














  • Sentiment is the dimension where MESO ranks best; there it ranks ahead of 95.59% of US stocks.
  • The strongest trend for MESO is in Growth, which has been heading down over the past 117 days.
  • MESO's current lowest rank is in the Quality metric (where it is better than 3.77% of US stocks).

MESO Stock Summary

  • MESOBLAST LTD's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 8.85% of US listed stocks.
  • With a price/sales ratio of 51.41, MESOBLAST LTD has a higher such ratio than 96.49% of stocks in our set.
  • Revenue growth over the past 12 months for MESOBLAST LTD comes in at -16.64%, a number that bests just 9.92% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to MESO, based on their financial statements, market capitalization, and price volatility, are RBBN, OPGN, KIQ, ATNX, and SPOK.
  • MESO's SEC filings can be seen here. And to visit MESOBLAST LTD's official web site, go to

MESO Valuation Summary

  • In comparison to the median Healthcare stock, MESO's price/sales ratio is 783.33% higher, now standing at 42.4.
  • Over the past 86 months, MESO's price/earnings ratio has gone up 1.5.

Below are key valuation metrics over time for MESO.

Stock Date P/S P/B P/E EV/EBIT
MESO 2022-11-25 42.4 0.9 -4.7 -6.5
MESO 2022-11-23 42.5 0.9 -4.8 -6.5
MESO 2022-11-22 41.4 0.9 -4.6 -6.3
MESO 2022-11-21 41.5 0.9 -4.6 -6.3
MESO 2022-11-18 39.4 0.8 -4.4 -6.0
MESO 2022-11-17 39.2 0.8 -4.4 -6.0

MESO Growth Metrics

    Its 2 year price growth rate is now at -74.12%.
  • The 5 year cash and equivalents growth rate now stands at 77.21%.
  • Its 2 year net cashflow from operations growth rate is now at -29.98%.
MESO's revenue has moved down $12,256,000 over the prior 30 months.

The table below shows MESO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 10.214 -65.782 -91.347
2022-03-31 9.983 -72.618 -91.952
2021-12-31 9.887 -82.97 -97.165
2021-12-31 9.887 -82.97 -97.165
2021-09-30 9.745 -98.12 -96.912
2021-09-30 9.745 -98.12 -96.912

MESO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MESO has a Quality Grade of F, ranking ahead of 0.82% of graded US stocks.
  • MESO's asset turnover comes in at 0.01 -- ranking 391st of 680 Pharmaceutical Products stocks.
  • RGEN, STAB, and OTLK are the stocks whose asset turnover ratios are most correlated with MESO.

The table below shows MESO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.010 1 -2.497
2021-03-31 0.009 1 -2.975
2020-12-31 0.024 1 -2.483
2020-09-30 0.023 1 -2.357
2020-06-30 0.047 1 -1.700
2020-06-30 0.047 1 -1.700

MESO Stock Price Chart Interactive Chart >

Price chart for MESO

MESO Price/Volume Stats

Current price $3.69 52-week high $6.77
Prev. close $3.70 52-week low $2.14
Day low $3.63 Volume 94,900
Day high $3.79 Avg. volume 73,372
50-day MA $3.06 Dividend yield N/A
200-day MA $3.37 Market Cap 543.99M

Mesoblast Limited (MESO) Company Bio

Mesoblast Ltd. has established a diverse portfolio of product candidates based on its proprietary allogeneic, off-the-shelf mesenchymal lineage cell-based technology, with multiple active Phase 3 clinical programs. Mesoblast's lead product candidates target major diseases with significant unmet medical needs despite existing therapies. These include chronic heart failure, chronic low back pain due to degenerative disc disease, and immune-mediated conditions such as acute graft versus host disease and biologic refractory rheumatoid arthritis. The company is based in Melbourne, Australia.

MESO Latest News Stream

Event/Time News Detail
Loading, please wait...

MESO Latest Social Stream

Loading social stream, please wait...

View Full MESO Social Stream

Latest MESO News From Around the Web

Below are the latest news stories about MESOBLAST LTD that investors may wish to consider to help them evaluate MESO as an investment opportunity.

Mesoblast Lead Product Shows Durable Long-Term Survival At Four Years In Kids With Graft Versus Host Disease

Mesoblast Limited (NASDAQ: MESO) announced top-line long-term survival results for remestemcel-L from its Phase 3 trial (GVHD-001) in children with steroid-refractory acute graft-versus-host disease (SR-aGVHD). The results showed durable survival through 4 years of follow-up. These new long-term survival data are a key component of the company's BLA resubmission to the FDA for remestemcel-L in treating children with SR-aGVHD. A four-year observational cohort survival study was performed on 51 ev

Yahoo | November 23, 2022

Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of children or adults with SR-aGVHD who received best available therapy (BAT) or the only approved agent in adults1-4These results reaffirm the potential significance of remestemcel-L as a life-saving therapy for children with SR-aGVHDThese long-term survival outcome

Yahoo | November 22, 2022

Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022

Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L These long-term survival outcomes are a cornerstone of the BLA resubmission to FDA for approval of remestemcel-L in the treatment of children with SR-aGVHD NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational high

Yahoo | November 22, 2022

Mesoblast Financial Results and Corporate Update Webcast

NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the first quarter ended September 30, 2022. The webcast will begin at 4.30pm EST, Tuesday, November 22; 8.30am AEDT, Wednesday, November 23, 2022. It can be accessed via: The archived webcast will be available on the Inve

Yahoo | November 21, 2022

Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022

Quarterly Activity ReportNEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended September 30, 2022. Financial Highlights Net cash usage for operating activities in the quarter was US$14.3 million; this represented a reduction of US$3.9 million, or 22%, on the comparative quarter in FY2022, and a reduction of $US8.0 million, or 47%

Yahoo | October 30, 2022

Read More 'MESO' Stories Here

MESO Price Returns

1-mo 28.13%
3-mo 25.94%
6-mo 11.14%
1-year -32.54%
3-year -40.29%
5-year -28.63%
YTD -23.13%
2021 -43.46%
2020 15.20%
2019 78.88%
2018 -29.45%
2017 9.16%

Continue Researching MESO

Here are a few links from around the web to help you further your research on Mesoblast Ltd's stock as an investment opportunity:

Mesoblast Ltd (MESO) Stock Price | Nasdaq
Mesoblast Ltd (MESO) Stock Quote, History and News - Yahoo Finance
Mesoblast Ltd (MESO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7293 seconds.